NasdaqGS:VIRBiotechs
Vir Biotechnology (VIR) Could Be 58% Below Fair Value On Q2 Profit Turnaround
Vir Biotechnology (VIR) is in focus after its second quarter 2026 report showed revenue of US$238.95 million and net income of US$80.08 million, compared with losses and minimal revenue a year earlier.
See our latest analysis for Vir Biotechnology.
At a share price of US$9.11, Vir Biotechnology has seen a 7 day share price return of 5.44% and a year to date share price return of 53.37%. The 1 year total shareholder return of 79.33% sits against weaker 3 and 5 year total shareholder returns,...